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The messenger molecule NO leads to an enhanced cGMP
production by stimulation of NO-sensitive guanylyl
cyclase (GC) and thereby causes relaxation of smooth
muscle and inhibition of platelet aggregation. In vascular
smooth muscle, cGMP synthesis is also stimulated by
natriuretic peptides, e.g. ANP, that activate particulate GC-
coupled receptors. The amplitude and duration of a cGMP
signal critically depends on cGMP degradation by phos-
phodiesterases with the cGMP-specific cGMP-binding
phosphodiesterase type 5 (PDE5) being of major impor-
tance in many cells. In platelets, a negative feed-back reg-
ulation in NO/cGMP-signalling has been described which
is caused by the activation of PDE5. Binding of cGMP to
the regulatory GAF-A domain of PDE5 leads to a long-last-
ing increase in catalytic activity. Consequently, the activa-
tion of PDE5 elicits a sustained desensitisation of the
signalling pathway in platelets towards further NO stim-
uli. Recently, a rapid NO-induced desensitisation as a
result of PDE5 activation has also been demonstrated in
smooth muscle-containing tissues.
Here, we compare the amounts of the principal constitu-
ents of the NO/cGMP signalling pathway (GC and PDE5)
in two different models of smooth muscle, i.e. aortic and
bronchial muscle. The expression levels of NO-sensitive
GC and PDE5 and the degree of PDE5 activation were
determined. Furthermore, the respective NO-induced
cGMP responses were determined in control and NO-
desensitized tissues.
Using organ bath experiments we investigate the physio-
logical relevance of the NO-induced desensitisation on
various relaxing stimuli. The NO-induced relaxation was
impaired by a short term NO pretreatment in aorta and
bronchus. In aortic tissue, ANP-mediated vasorelaxation
was also impaired showing that desensitisation does not
occur on the level of NO-sensitive GC. The direct activa-
tion of cGMP-dependent protein kinase caused similar
responses of relaxation in NO-pretreated and control ves-
sels. Therefore, the activation of PDE5 is sufficient to
explain the observed NO-induced desensitisation of
smooth muscle relaxation.
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